
scPharmaceuticals SCPH
Quarterly report 2025-Q2
added 08-07-2025
scPharmaceuticals Interest Expense 2011-2026 | SCPH
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense scPharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.12 M | 3.3 M | 2.58 M | 2.59 M | 1.77 M | 1.43 M | 797 K | 6.51 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.12 M | 797 K | 3.39 M |
Quarterly Interest Expense scPharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.4 M | 1.38 M | - | 1.85 M | 2.13 M | 2.1 M | - | 2.06 M | 2.01 M | 1.96 M | - | 377 K | 447 K | 518 K | - | 667 K | 651 K | 636 K | - | 655 K | 639 K | 636 K | - | 398 K | 369 K | 354 K | - | 360 K | 359 K | 342 K | - | 329 K | 132 K | 10 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.13 M | 10 K | 876 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
ACADIA Pharmaceuticals
ACAD
|
1.82 M | $ 22.42 | 1.49 % | $ 3.72 B | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
5.2 M | $ 326.77 | 2.27 % | $ 42.8 B | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.85 | 2.39 % | $ 9.26 B | ||
|
CymaBay Therapeutics
CBAY
|
18.9 M | - | - | $ 3.45 B | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 20.33 | -1.21 % | $ 950 M | ||
|
Aquestive Therapeutics
AQST
|
6.55 M | $ 4.16 | 0.73 % | $ 445 M | ||
|
Avid Bioservices
CDMO
|
4.34 M | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
5.81 M | - | - | $ 1.41 B | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 24.49 | 5.24 % | $ 3.12 B | ||
|
Cabaletta Bio
CABA
|
2 M | $ 3.07 | -0.16 % | $ 308 M | ||
|
Checkpoint Therapeutics
CKPT
|
344 K | - | - | $ 169 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Concert Pharmaceuticals
CNCE
|
-309 K | - | - | $ 401 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.48 | 8.46 % | $ 394 M | ||
|
CTI BioPharma Corp.
CTIC
|
13.1 M | - | - | $ 1.2 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
354 K | - | -4.36 % | $ 27 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
16.4 M | - | - | $ 2.18 B | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.71 | 5.51 % | $ 17 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Dynavax Technologies Corporation
DVAX
|
293 K | - | - | $ 2.02 B | ||
|
Akari Therapeutics, Plc
AKTX
|
100 K | $ 3.75 | -1.32 % | $ 252 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M |